Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Infectious Disease
•
Non-Tubercular Mycobacteria
Is there a role for dual antibiotic treatment with ethambutol and macrolide only, as opposed to three-drug antibiotic therapy, in the treatment of treatment-naive pulmonary MAC without cavitary disease?
Related Questions
In which patients do you prefer daily standard three-drug therapy for non-cavitary pulmonary MAC as opposed to three times a week dosing?
Is there a role for liposomal inhaled amikacin for the treatment of cavitary MAC disease?
Do you typically adjust or hold immunosuppression in a well-controlled RA patient who is being treated for Mycobacterium avium-intracellulare (MAI)?
What is your preferred third antimicrobial agent for a patient with treatment-naive pulmonary MAC without cavitary disease and strict contraindications to utilization of rifampin or rifabutin?
What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?
What is your approach to treatment of macrolide-sensitive localized bone/joint MAC disease?
Do you recommend screening patients in high endemic regions for coccidioidomycosis prior to initiation of anti-TNF inhibitor therapy?
How long do you treat uncomplicated gram-negative rod bacteremia in solid organ transplant recipients?
What is the risk of serious bacterial infection in a febrile solid tumor patient who has not yet started cancer-directed therapy and has normal cell counts with no central line?
For how long do you treat an early spinal hardware infection secondary to MSSA after operative washout and retention of hardware?
